GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

INSM · Sep 30, 2026

INSMED Inc. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]

Inspectable configuration

State dimensions

Filing0001104506-26-000047General Corporate

Debt relative to revenue5thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.debt_to_revenue

104.26% · OPTIONAL · VALID

Capex intensity5thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.07% · OPTIONAL · VALID

Operating cash generation100thOwn-history percentile · N=20

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-6.95% · OPTIONAL · VALID

Revenue growth95thOwn-history percentile · N=20

Evidence method

Yoy · gp.fundamentals.revenue

268.43% · CORE · VALID

Inventory pressure20thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

31.26% · OPTIONAL · VALID

Gross margin100thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.gross_margin

85.09% · CORE · VALID

Operating margin95thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.operating_margin

-17.04% · CORE · VALID

R&D intensity5thOwn-history percentile · N=20

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

51.48% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

7.86% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History8 statesSelf-history eligible

Dec 31, 20180/8 normalizedLevel 3 Mar 31, 20190/8 normalizedLevel 3 Jun 30, 20190/8 normalizedLevel 3 Sep 30, 20190/8 normalizedLevel 3 Dec 31, 20190/9 normalizedLevel 3 Mar 31, 20200/9 normalizedLevel 3 Jun 30, 20200/9 normalizedLevel 3 Sep 30, 20269/9 normalizedLevel 4

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 128.50%
Current: 104.26%
Delta: -24.24%

Capex Intensity Decreased

Previous: 1.47%
Current: 1.07%
Delta: -0.40%

Cash Generation Increased

Previous: -20.88%
Current: -6.95%
Delta: 13.92%

Growth Decreased

Previous: 296.11%
Current: 268.43%
Delta: -27.69%

Inventory Pressure Decreased

Previous: 33.46%
Current: 31.26%
Delta: -2.20%

Margin Increased

Previous: 84.20%
Current: 85.09%
Delta: 0.88%

Profitability Decreased

Previous: -0.36%
Current: -17.04%
Delta: -16.68%

R And D Intensity Increased

Previous: 49.36%
Current: 51.48%
Delta: 2.11%

Sbc Intensity Decreased

Previous: 9.70%
Current: 7.86%
Delta: -1.84%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Mar 31, 2026

Similarity: 97%
Compared: 9 dimensions
Coverage: 100%

Growth 5.0 · Margin 0.0 · Profitability 5.0 · Sbc Intensity 0.0 · Capex Intensity 0.0 · Cash Generation 0.0 · R And D Intensity 5.0 · Inventory Pressure 5.0 · Balance Sheet Leverage 0.0

Sep 30, 2025

Similarity: 73%
Compared: 9 dimensions
Coverage: 100%

Growth 5.0 · Margin 5.0 · Profitability 75.0 · Sbc Intensity 15.0 · Capex Intensity 0.0 · Cash Generation 20.0 · R And D Intensity 5.0 · Inventory Pressure 5.0 · Balance Sheet Leverage 5.0

Sep 30, 2022

Similarity: 62%
Compared: 9 dimensions
Coverage: 100%

Growth 13.2 · Margin 26.7 · Profitability 48.3 · Sbc Intensity 40.0 · Capex Intensity 5.0 · Cash Generation 6.7 · R And D Intensity 68.3 · Inventory Pressure 40.0 · Balance Sheet Leverage 41.7

Dec 31, 2020

Similarity: 62%
Compared: 8 dimensions
Coverage: 89%

Margin 75.0 · Profitability 32.5 · Sbc Intensity 37.5 · Capex Intensity 7.5 · Cash Generation 12.5 · R And D Intensity 57.5 · Inventory Pressure 7.5 · Balance Sheet Leverage 5.0

Dec 31, 2021

Similarity: 53%
Compared: 9 dimensions
Coverage: 100%

Growth 45.0 · Margin 58.3 · Profitability 53.3 · Sbc Intensity 41.7 · Capex Intensity 28.3 · Cash Generation 66.7 · R And D Intensity 70.0 · Inventory Pressure 3.3 · Balance Sheet Leverage 11.7

Research Graph

Related governed research

Analogous To · INSM state analogue 4 →Analogous To · INSM state analogue 1 →Analogous To · INSM state analogue 3 →Compared To · Pharmaceutical Preparations peers →Analogous To · INSM state analogue 5 →Analogous To · INSM state analogue 2 →Derived From · INSM Company Quality Vector →Has State · INSMED Inc →Transitioned To · INSM BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · INSM CAPEX_INTENSITY_DECREASED →Transitioned To · INSM CASH_GENERATION_INCREASED →Transitioned To · INSM GROWTH_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.